NO20090574L - Nye proteinkonjugater og fremgangsmater for fremstilling derav - Google Patents

Nye proteinkonjugater og fremgangsmater for fremstilling derav

Info

Publication number
NO20090574L
NO20090574L NO20090574A NO20090574A NO20090574L NO 20090574 L NO20090574 L NO 20090574L NO 20090574 A NO20090574 A NO 20090574A NO 20090574 A NO20090574 A NO 20090574A NO 20090574 L NO20090574 L NO 20090574L
Authority
NO
Norway
Prior art keywords
protein conjugates
processes
preparation
novel protein
heteroarylamines
Prior art date
Application number
NO20090574A
Other languages
English (en)
Inventor
Florencio Zaragoza Dorwald
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of NO20090574L publication Critical patent/NO20090574L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet reduktiv aminering av peptidavledede aldehyder med aniliner eller heteroarylaminer som inneholder en egenskapsmodifiserende gruppe som tilveiebringer nye, hydrolytisk stabile proteinkonjugater som er egnet for terapi.
NO20090574A 2006-07-07 2009-02-05 Nye proteinkonjugater og fremgangsmater for fremstilling derav NO20090574L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06116776 2006-07-07
PCT/EP2007/056819 WO2008003750A2 (en) 2006-07-07 2007-07-05 New protein conjugates and methods for their preparation

Publications (1)

Publication Number Publication Date
NO20090574L true NO20090574L (no) 2009-03-30

Family

ID=38701511

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090574A NO20090574L (no) 2006-07-07 2009-02-05 Nye proteinkonjugater og fremgangsmater for fremstilling derav

Country Status (15)

Country Link
US (1) US9175061B2 (no)
EP (1) EP2040757A2 (no)
JP (1) JP5252458B2 (no)
KR (1) KR20100014215A (no)
CN (1) CN101495155A (no)
AU (1) AU2007271150A1 (no)
BR (1) BRPI0713963A2 (no)
CA (1) CA2655188A1 (no)
IL (1) IL195839A0 (no)
MX (1) MX2008016169A (no)
NO (1) NO20090574L (no)
RU (1) RU2009103198A (no)
TW (1) TW200815477A (no)
WO (1) WO2008003750A2 (no)
ZA (1) ZA200810821B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR9812267B1 (pt) 1997-07-14 2013-11-26 Hormônio de crescimento recombinante.
EP1144613B2 (en) 1999-01-14 2020-05-06 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP5977945B2 (ja) 2008-08-06 2016-08-24 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有するコンジュゲートタンパク質
ES2542202T3 (es) 2009-01-22 2015-08-03 Novo Nordisk Health Care Ag Compuestos de hormonas de crecimiento estables
JP6086528B2 (ja) * 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
JP5875527B2 (ja) 2010-01-22 2016-03-02 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ｉｎ−ｖｉｖｏにおける効力が延長された成長ホルモン
AU2011208620B2 (en) 2010-01-22 2015-04-16 Novo Nordisk Health Care Ag Stable growth hormone compounds
AU2012210624A1 (en) * 2011-01-26 2013-07-11 Novo Nordisk A/S Leptin derivatives
EP2842546A4 (en) 2012-04-27 2015-12-30 Univ Tokyo UNITARY STRUCTURE-TYPE PHARMACEUTICAL COMPOSITION FOR NUCLEIC ACID ADMINISTRATION
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤
WO2016034534A1 (en) * 2014-09-01 2016-03-10 Novo Nordisk Health Care Ag Lysine rich basic pre-sequences
EP3250636B1 (en) * 2015-01-27 2020-05-06 Hewlett-Packard Development Company, L.P. Polymeric amine synergists
WO2016122455A1 (en) 2015-01-27 2016-08-04 Hewlett-Packard Development Company, L.P. Polymeric photoactive agents
WO2016122454A1 (en) 2015-01-27 2016-08-04 Hewlett-Packard Development Company, L.P. Polymeric photo active agents
EP3677268A4 (en) 2017-08-31 2021-04-21 The University Of Tokyo UNIT POLYIONIC COMPLEX FILLED WITH NUCLEIC ACID

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DK173435B1 (da) 1983-08-17 2000-10-23 Wellcome Found Injicerbare præparater samt fremgangsmåder til potentiering af administrering af et hormon til normale hvirveldyr eller til
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
US6673347B1 (en) 1986-04-30 2004-01-06 Gryphon Therapeutics Polypeptide and protein derivatives and process for their preparation
WO1990003401A1 (en) 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
NZ246556A (en) 1991-12-20 1996-03-26 Novo Nordisk As Pharmaceutical composition of a growth hormone and histidine
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
WO1995032003A1 (en) 1994-05-24 1995-11-30 Amgen Boulder Inc. Modified insulin-like growth factors
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
US5795560A (en) * 1994-11-01 1998-08-18 Neorx Corporation Targeting protein-diagnostic/therapeutic agent conjugates having Schiff base linkages
EP0788375A2 (en) 1994-11-09 1997-08-13 Robin Ewart Offord Functionalized polymers for site-specific attachment
WO1996017929A1 (en) 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
JP4410852B2 (ja) 1996-08-02 2010-02-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 単一の共有結合ｎ末端水溶性ポリマーを有するポリペプチド
WO1998013381A1 (fr) 1996-09-26 1998-04-02 Ajinomoto Co., Inc. Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
CA2723664A1 (en) 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
MXPA02012795A (es) 2000-06-28 2004-07-30 Teva Pharma Carvedilol.
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
US7049285B2 (en) 2001-10-31 2006-05-23 Myung-Ok Park Biocompatible polymers including peptide spacer
IL162031A0 (en) * 2001-11-20 2005-11-20 Pharmacia Corp Chemically-modified human growth hormone conjugates
WO2004000366A1 (en) 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
AU2003256566A1 (en) 2002-07-16 2004-02-02 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
JP4430344B2 (ja) 2002-09-09 2010-03-10 独立行政法人科学技術振興機構 多岐用途型リンカー化合物及びリガンド、並びにそれらの製造方法
TWI281864B (en) 2002-11-20 2007-06-01 Pharmacia Corp N-terminally monopegylated human growth hormone conjugates and process for their preparation
KR20060032140A (ko) 2003-05-30 2006-04-14 센토코 인코포레이티드 트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005014024A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
CN1528797A (zh) 2003-09-28 2004-09-15 石油大学(华东) 含氟碳基团的超高分子量水溶性疏水缔合型聚合物及其制备方法
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
EP2263684A1 (en) 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
JP2007508250A (ja) 2003-10-10 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 持続性放出製剤における長期作用性分子
CN1243022C (zh) 2003-10-17 2006-02-22 华东师范大学 生物修饰重组人生长激素复合物及其制备方法
US20070105770A1 (en) 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
KR20070027621A (ko) 2004-06-08 2007-03-09 알자 코포레이션 4-성분 축합 반응에 의한 고분자 콘쥬게이트의 제조
WO2006042847A2 (en) 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
EP1805216A2 (en) 2004-10-18 2007-07-11 Novo Nordisk A/S Growth hormone conjugates
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
CN103690936A (zh) 2004-12-22 2014-04-02 Ambrx公司 经修饰的人类生长激素
EP1893239A2 (en) 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of growth hormone
BRPI0615351A2 (pt) 2005-08-30 2011-05-17 Novo Nordisk Healthcare Ag formulações lìquidas de hormÈnio do crescimento peguilado
AU2006201635A1 (en) 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation

Also Published As

Publication number Publication date
RU2009103198A (ru) 2010-08-20
US9175061B2 (en) 2015-11-03
KR20100014215A (ko) 2010-02-10
TW200815477A (en) 2008-04-01
MX2008016169A (es) 2009-01-15
CA2655188A1 (en) 2008-01-10
IL195839A0 (en) 2009-09-01
ZA200810821B (en) 2009-12-30
US20110144017A1 (en) 2011-06-16
CN101495155A (zh) 2009-07-29
JP5252458B2 (ja) 2013-07-31
EP2040757A2 (en) 2009-04-01
WO2008003750A2 (en) 2008-01-10
AU2007271150A1 (en) 2008-01-10
BRPI0713963A2 (pt) 2012-11-27
JP2009542769A (ja) 2009-12-03
WO2008003750A3 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20090574L (no) Nye proteinkonjugater og fremgangsmater for fremstilling derav
CY1123952T1 (el) Απομονωση και καθαρισμος αντισωματων αντι-il-13 με την χρηση χρωματογραφιας χημικης συγγενειας πρωτεινης α
ECSP088733A (es) Anticuerpos anti-5t4 y usos de los mismos
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
NO20092611L (no) Krystallinsk faststoff Rasagilin base
BRPI0508064A (pt) flavivìrus, composição de vacina e molécula de ácido nucléico
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
MX2009012843A (es) Moleculas de union especificas de virus sincitial respiratorio y medios para producirlas.
CR20120371A (es) Antagonistas de pcsk9
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
BRPI0809366A8 (pt) polipeptídeos interligados
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
DK2135091T3 (da) MS-fremgangsmåder til evaluering af glykaner
TW200740458A (en) Vaccination against dengue virus infection
WO2010017387A3 (en) Lapatinib, salts thereof, processes and intermediates for their preparation
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
CU20120021A7 (es) Derivados amido espirocíclicos
WO2011019932A3 (en) Compositions and methods for the therapy and diagnosis of influenza
BRPI0815378A2 (pt) as160 como proteína do tipo as160, sistemas de teste, métodos e usos envolvendo a mesma para identificação de terapêutica para diabetes tipo 2
SV2005002015A (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo - ref. wyth0008-504 (am101302)
BR112012013325A2 (pt) Composição farmacêutica e uso
BRPI0921371A2 (pt) Células-tronco para uso terapêutico que são derivados de monócito humano, e método para induzir as mesmas.
BR112012012783A2 (pt) produto de reação não reticulado de um composto epóxi e oxetano e um silicone amino